In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) closed at $14.26 up 2.52% from its previous closing price of $13.91. In other words, the price has increased by $2.52 from its previous closing price. On the day, 0.93 million shares were traded. RDY stock price reached its highest trading level at $14.265 during the session, while it also had its lowest trading level at $14.12.
Ratios:
For a deeper understanding of Dr. Reddy’s Laboratories Ltd. ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.36 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RDY now has a Market Capitalization of 11881075712 and an Enterprise Value of -2478391552. As of this moment, Dr.’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.84, and their Forward P/E ratio for the next fiscal year is 22.36. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.02 while its Price-to-Book (P/B) ratio in mrq is 2.92. Its current Enterprise Value per Revenue stands at -0.007 whereas that against EBITDA is -0.028.
Stock Price History:
The Beta on a monthly basis for RDY is 0.32, which has changed by -0.12547529 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, RDY has reached a high of $16.85, while it has fallen to a 52-week low of $12.26. The 50-Day Moving Average of the stock is -3.59%, while the 200-Day Moving Average is calculated to be -0.04%.
Shares Statistics:
For the past three months, RDY has traded an average of 1.54M shares per day and 1365090 over the past ten days. A total of 834.58M shares are outstanding, with a floating share count of 832.31M. Insiders hold about 0.00% of the company’s shares, while institutions hold 14.52% stake in the company. Shares short for RDY as of 1753920000 were 9892750 with a Short Ratio of 6.44, compared to 1751241600 on 10941723. Therefore, it implies a Short% of Shares Outstanding of 9892750 and a Short% of Float of 2.31.
Dividends & Splits
According to the company, the forward annual dividend rate for RDY is 0.09, from 8.0 in the trailing year. Against a Trailing Annual Dividend Yield of 0.5751258The stock’s 5-year Average Dividend Yield is 0.72. The current Payout Ratio is 8.90% for RDY, which recently paid a dividend on 2025-07-25 with an ex-dividend date of 2025-07-25. Stock splits for the company last occurred on 2024-11-05 when the company split stock in a 5:1 ratio.
Analysts are recommending an EPS of between $68.43 and $68.43 for the fiscal current year, implying an average EPS of $68.43. EPS for the following year is $54.78, with 1.0 analysts recommending between $54.78 and $54.78.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $88.11B this quarter.It ranges from a high estimate of $90.33B to a low estimate of $86.32B. As of the current estimate, Dr. Reddy’s Laboratories Ltd. ADR’s year-ago sales were $80.16BFor the next quarter, 4 analysts are estimating revenue of $84.87B. There is a high estimate of $89.02B for the next quarter, whereas the lowest estimate is $81.82B.
A total of 37 analysts have provided revenue estimates for RDY’s current fiscal year. The highest revenue estimate was $364.68B, while the lowest revenue estimate was $329.41B, resulting in an average revenue estimate of $344.21B. In the same quarter a year ago, actual revenue was $325.54BBased on 36 analysts’ estimates, the company’s revenue will be $349.16B in the next fiscal year. The high estimate is $385.09B and the low estimate is $325.4B.
